SCHEMBL4475841

SCHEMBL4475841

CN(CCN1CCC(OC(=O)N(c2ccccc2-c2ccccc2)N(C(=O)O)c2ccccc2-c2ccccc2)CC1)C(=O)c1cccc(C(=O)NCCNCC2CC2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 1/20 0.43
SLC5A7 Q9GZV3 1/20 0.39
CHRM3 P20309 6/20 0.38
ADRB2 P07550 1/20 0.38
HTR7 P34969 3/20 0.38
HTR1A P08908 1/20 0.38
CARM1 Q86X55 1/20 0.38
PRMT6 Q96LA8 1/20 0.38
DRD2 P14416 1/20 0.38
CCR3 P51677 1/20 0.37
SMYD2 Q9NRG4 1/20 0.36
TMEM97 Q5BJF2 2/20 0.36
HDAC3 O15379 1/20 0.36
HDAC4 P56524 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC7 Q8WUI4 1/20 0.36
HDAC2 Q92769 1/20 0.36
HDAC10 Q969S8 1/20 0.36
HDAC11 Q96DB2 1/20 0.36
HDAC8 Q9BY41 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4490830 0.94 CHRM2 (0.44) CHRM2SLC5A7CHRM3ADRB2HTR7
SCHEMBL4479676 0.92 CARM1 (0.45) CHRM2SLC5A7CHRM3ADRB2HTR7
SCHEMBL4493960 0.91 CHRM2 (0.42) CHRM2SLC5A7CHRM3ADRB2HTR7
SCHEMBL4493963 0.90 CHRM3 (0.45) CHRM2SLC5A7CHRM3ADRB2
SCHEMBL4491995 0.90 CHRM2 (0.41) CHRM2SLC5A7CHRM3ADRB2HTR7
SCHEMBL4483079 0.90 CHRM3 (0.44) CHRM2SLC5A7CHRM3ADRB2HTR7
SCHEMBL4480089 0.89 CHRM2 (0.43) CHRM2SLC5A7CHRM3ADRB2HTR7
SCHEMBL4472532 0.89 CHRM2 (0.41) CHRM2SLC5A7CHRM3ADRB2HTR7
SCHEMBL4494191 0.89 CHRM2 (0.43) CHRM2SLC5A7CHRM3ADRB2HTR1A
SCHEMBL4474955 0.89 CHRM2 (0.40) CHRM2SLC5A7CHRM3ADRB2HTR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7632847-B2 Bronchodilators; treating chronic obstructive pulmonary disease or asthma; long duration of action; reduced side effects, such as dry-mouth and constipation; e.g. biphenyl-2-ylcarbamic acid 1-(2-(3-[3-(4-hydroxybenzylamino)propionylamino]benzoylamino)ethyl)piperidin-4-yl ester THERAVANCE, INC. (US) 2009-12-15 US disclosed